ReviewDermatology and therapy2023
Use of 5-Alpha Reductase Inhibitors in Dermatology: A Narrative Review.
Review in Dermatology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Pathophysiology, conventional treatments, and evidence-based herbal remedies of hair loss with a systematic review of controlled clinical trials.Naunyn-Schmiedeberg's archives of pharmacology · 2025Pooled it
- Hair Growth-Supporting and Follicle-Protective Potential of a Botanical-Based Supplement Ingredient: In Vitro, Ex Vivo, and Molecular Docking Studies.Biomolecules · 2026Article
- Lipid nanocarriers as innovative strategies for hair regrowth.Discover nano · 2026Review
- Persistent Sexual and Psychological Symptoms After Finasteride Discontinuation: A Cross-Sectional Observational Study.Journal of clinical medicine · 2026Article
- Overview of Short Peptides for Hair Loss.Biomedicines · 2026Review
- Safety of Alopecia Treatments in Patients with Breast Cancer and High-Risk Women: A Review.American journal of clinical dermatology · 2025Review
- Phytochemicals for Hair Health Targeting Growth Signaling Molecules in Hair Follicular Stem Cells: A New Strategy for Hair Growth.Journal of microbiology and biotechnology · 2025Review
- Article
- Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Evaluation of Efficacy of Water-Soluble Fraction ofAntioxidants (Basel, Switzerland) · 2025Article
- Combating post-COVID hair loss: topical and oral treatments for hair regeneration.Irish journal of medical science · 2025Article
- Androgenetic Alopecia: An Update on Pathogenesis and Pharmacological Treatment.Drug design, development and therapy · 2025Review
- Kopexil vs minoxidil:BioImpacts : BI · 2025Article
- Exosomes from human umbilical cord mesenchymal stem cells promote the growth of human hair dermal papilla cells.PloS one · 2025Article
- Can Plant Extracts Help Prevent Hair Loss or Promote Hair Growth? A Review Comparing Their Therapeutic Efficacies, Phytochemical Components, and Modulatory Targets.Molecules (Basel, Switzerland) · 2024Review
- Stem cell-based approaches for alopecia: A narrative review of current and emerging treatment strategies.Cell transplantationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Finasteride and dutasteride are 5-alpha reductase selective inhibitors (5ARIs). They were introduced as therapeutic agents for the treatment of benign prostatic hyperplasia in 1992 and 2002, respectively; finasteride has also been approved for the treatment of androgenetic alopecia since early 2000. These agents inhibit the conversion of testosterone (T) to 5α-dihydrotestosterone (5α-DHT), limiting steroidogenesis and playing a crucial role in the physiological function of the neuroendocrine system. Therefore, it has been proposed that blocking androgen synthesis with the use of 5ARIs would be beneficial in the treatment of various diseases related to states of hyperandrogenism. This review describes the dermatological pathologies in which 5ARIs have been used as part of the treatment, evaluation of the efficacy, and knowledge of the safety profile. Specifically, we discuss the application of 5ARIs in androgenetic alopecia, acne, frontal fibrosing alopecia, hirsutism, and the implications of adverse events associated with its use to inform about the applications of 5ARIs in general dermatology practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.